Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections.

Kers JA, DeFusco AW, Park JH, Xu J, Pulse ME, Weiss WJ, Handfield M.

PLoS One. 2018 Jun 12;13(6):e0197467. doi: 10.1371/journal.pone.0197467. eCollection 2018.

2.

Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection.

Kers JA, Sharp RE, Defusco AW, Park JH, Xu J, Pulse ME, Weiss WJ, Handfield M.

Front Microbiol. 2018 Mar 16;9:415. doi: 10.3389/fmicb.2018.00415. eCollection 2018.

3.

In vivo assessment of SMT19969 in a hamster model of clostridium difficile infection.

Weiss W, Pulse M, Vickers R.

Antimicrob Agents Chemother. 2014 Oct;58(10):5714-8. doi: 10.1128/AAC.02903-14. Epub 2014 Jul 14.

4.

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.

Sattar A, Thommes P, Payne L, Warn P, Vickers RJ.

J Antimicrob Chemother. 2015;70(6):1757-62. doi: 10.1093/jac/dkv005. Epub 2015 Feb 3.

5.

Activity of RBx 11760, a novel biaryl oxazolidinone, against Clostridium difficile.

Mathur T, Kumar M, Barman TK, Kumar GR, Kalia V, Singhal S, Raj VS, Upadhyay DJ, Das B, Bhatnagar PK.

J Antimicrob Chemother. 2011 May;66(5):1087-95. doi: 10.1093/jac/dkr033. Epub 2011 Mar 3.

PMID:
21393140
6.

Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.

Crowther GS, Baines SD, Todhunter SL, Freeman J, Chilton CH, Wilcox MH.

J Antimicrob Chemother. 2013 Jan;68(1):168-76. doi: 10.1093/jac/dks359. Epub 2012 Sep 10.

PMID:
22966180
7.

Novel therapeutic strategies for Clostridium difficile infections.

Ünal CM, Steinert M.

Expert Opin Ther Targets. 2016;20(3):269-85. doi: 10.1517/14728222.2016.1090428. Epub 2015 Nov 13. Review.

PMID:
26565670
8.

Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.

Warren CA, van Opstal E, Ballard TE, Kennedy A, Wang X, Riggins M, Olekhnovich I, Warthan M, Kolling GL, Guerrant RL, Macdonald TL, Hoffman PS.

Antimicrob Agents Chemother. 2012 Aug;56(8):4103-11. doi: 10.1128/AAC.00360-12. Epub 2012 May 14.

9.

In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.

Locher HH, Seiler P, Chen X, Schroeder S, Pfaff P, Enderlin M, Klenk A, Fournier E, Hubschwerlen C, Ritz D, Kelly CP, Keck W.

Antimicrob Agents Chemother. 2014;58(2):892-900. doi: 10.1128/AAC.01830-13. Epub 2013 Nov 25.

10.

Carboxyl Analogue of Mutacin 1140, a Scaffold for Lead Antibacterial Discovery.

Escano J, Ravichandran A, Salamat B, Smith L.

Appl Environ Microbiol. 2017 Jun 30;83(14). pii: e00668-17. doi: 10.1128/AEM.00668-17. Print 2017 Jul 15.

11.

Infection of hamsters with historical and epidemic BI types of Clostridium difficile.

Razaq N, Sambol S, Nagaro K, Zukowski W, Cheknis A, Johnson S, Gerding DN.

J Infect Dis. 2007 Dec 15;196(12):1813-9. doi: 10.1086/523106.

PMID:
18190262
12.

Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains.

Secore S, Wang S, Doughtry J, Xie J, Miezeiewski M, Rustandi RR, Horton M, Xoconostle R, Wang B, Lancaster C, Kristopeit A, Wang SC, Christanti S, Vitelli S, Gentile MP, Goerke A, Skinner J, Strable E, Thiriot DS, Bodmer JL, Heinrichs JH.

PLoS One. 2017 Jan 26;12(1):e0170640. doi: 10.1371/journal.pone.0170640. eCollection 2017.

13.

Refinement of the hamster model of Clostridium difficile disease.

Douce G, Goulding D.

Methods Mol Biol. 2010;646:215-27. doi: 10.1007/978-1-60327-365-7_14.

PMID:
20597012
14.

Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection.

Cherian PT, Wu X, Yang L, Scarborough JS, Singh AP, Alam ZA, Lee RE, Hurdle JG.

J Antimicrob Chemother. 2015 Nov;70(11):3061-9. doi: 10.1093/jac/dkv231. Epub 2015 Aug 18.

15.

Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.

Warn P, Thommes P, Sattar A, Corbett D, Flattery A, Zhang Z, Black T, Hernandez LD, Therien AG.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6471-6482. doi: 10.1128/AAC.00974-16. Print 2016 Nov.

16.

Nonantimicrobial drug targets for Clostridium difficile infections.

Darkoh C, Deaton M, DuPont HL.

Future Microbiol. 2017 Sep;12:975-985. doi: 10.2217/fmb-2017-0024. Epub 2017 Jul 31.

17.

Acyldepsipeptide antibiotics as a potential therapeutic agent against Clostridium difficile recurrent infections.

Gil F, Paredes-Sabja D.

Future Microbiol. 2016 Sep;11:1179-89. doi: 10.2217/fmb-2016-0064. Epub 2016 Aug 22. Review.

PMID:
27546386
18.

Clinical, epidemiological and microbiological characteristics of relapse and re-infection in Clostridium difficile infection.

Gómez S, Chaves F, Orellana MA.

Anaerobe. 2017 Dec;48:147-151. doi: 10.1016/j.anaerobe.2017.08.012. Epub 2017 Aug 19.

PMID:
28830842
19.

Models for the study of Clostridium difficile infection.

Best EL, Freeman J, Wilcox MH.

Gut Microbes. 2012 Mar-Apr;3(2):145-67. doi: 10.4161/gmic.19526. Epub 2012 Mar 1. Review.

20.

Antibacterial and Solubility Optimization of Thiomuracin A.

LaMarche MJ, Leeds JA, Brewer J, Dean K, Ding J, Dzink-Fox J, Gamber G, Jain A, Kerrigan R, Krastel P, Lee K, Lombardo F, McKenney D, Neckermann G, Osborne C, Palestrant D, Patane MA, Rann EM, Robinson Z, Schmitt E, Stams T, Tiamfook S, Yu D, Whitehead L.

J Med Chem. 2016 Jul 28;59(14):6920-8. doi: 10.1021/acs.jmedchem.6b00726. Epub 2016 Jul 12.

PMID:
27355833

Supplemental Content

Support Center